Semax is a Russian-developed neuropeptide, approved as a pharmaceutical in Russia and Ukraine, including for stroke recovery. It stimulates BDNF and NGF synthesis, upregulates serotonin and dopamine receptors, and activates PDGF for neuroprotection, which is a lot of mechanism stacked into one small molecule. There is no Western RCT, so the record behind it comes from Russia, Ukraine and some CIS states.
- Approved as a pharmaceutical in Russia and Ukraine, including for stroke recovery, not just cognition.Russian/Ukrainian approval
- Stimulates BDNF and NGF synthesis, the growth factors that drive neuroplasticity research.PubMed: Semax
- Upregulates serotonin and dopamine receptors and activates PDGF for neuroprotection.PubMed: Semax
- Reported effects arrive fast, with mental clarity noted within hours and cognitive changes building across 2-4 weeks, alongside a brief headache in the first one to three days described as typical.researchdosing
- A US compounding advisory panel voted 8-5 in July 2026 to recommend it for the 503A bulks list, advisory only with FDA rulemaking pending.PCAC vote, Jul 2026